Business Context and Reporting Period
This Form 8-K Current Report was filed by Revelation Biosciences, Inc. on October 16, 2024. The filing addresses regulatory notices received from The Nasdaq Stock Market LLC regarding the Company's compliance with continued listing standards.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or margin figures. However, it references the following financial thresholds and statuses:
- Stockholders' Equity Requirement: Nasdaq requires a minimum of $2,500,000 in stockholders' equity.
- Minimum Bid Price Requirement: Nasdaq requires a minimum bid price of $1.00 per share.
- Current Status: The Company states it believes it satisfied the Stockholders' Equity Requirement as of September 30, 2024, following financing activities in the third quarter.
Material Changes and Listing Deficiencies
The Company received two deficiency letters from Nasdaq:
- Minimum Bid Price Deficiency (Oct 16, 2024): The Company failed to maintain the $1.00 minimum bid price. Due to a reverse stock split with a cumulative ratio of 250:1 or more within the prior two years, the Company is ineligible for the standard 180-day compliance period.
- Stockholders' Equity Deficiency (Aug 14, 2024): The Company previously failed to meet the $2,500,000 equity requirement or alternative standards (market value of $35 million or net income of $500,000). This deficiency serves as an additional basis for potential delisting.
Outlook, Management Commentary, and Risks
Management Action: The Company intends to request a hearing before an independent Nasdaq Hearings Panel to appeal the deficiency letters. This appeal will stay any suspension or delisting action pending the conclusion of the hearing process.
Risks and Contingencies:
- There is no assurance the Company will ultimately regain compliance with all applicable listing requirements.
- Despite the deficiencies, the Company's common stock (REVB) and warrants (REVBW) will continue to trade on The Nasdaq Capital Market during the appeal process.
Investor Verification Checklist
- Verify the current trading price of REVB to assess the severity of the bid price deficiency.
- Confirm the Company's most recent audited financial statements to validate the claim of meeting the $2.5 million stockholders' equity threshold as of September 30, 2024.
- Monitor the status of the appeal hearing request and any subsequent rulings from the Nasdaq Hearings Panel.
- Review the Company's recent financing activities to understand the capital raised in Q3 2024.